

van den Heuvel Odile (Orcid ID: 0000-0002-9804-7653)
Francks Clyde (Orcid ID: 0000-0002-9098-890X)
Spalletta Gianfranco (Orcid ID: 0000-0002-7432-4249)
Hoogman Martine (Orcid ID: 0000-0002-1261-7628)
Thomopoulos Sophia (Orcid ID: 0000-0002-0046-4070)

Title:

An overview of the first five years of the ENIGMA Obsessive-Compulsive Disorder working group: the power of worldwide collaboration

Authors:

Odile A. van den Heuvel, MD PhD^{1,2#}, Premika S.W. Boedhoe, PhD¹, Sara Bertolin, MD³, Willem B. Bruin, MSc⁴, Clyde Francks, PhD^{5,6}, Iliyan Ivanov, MD⁷, Neda Jahanshad, PhD⁸, Xiang-Zhen Kong, PhD⁵, Jun Soo Kwon, MD PhD^{9,10}, Joseph O'Neill, PhD¹¹, Tomas Paus, MD PhD¹², Yash Patel, BHSc¹², Fabrizio Piras, PhD¹³, Lianne Schmaal, PhD^{14,15}, Carles Soriano-Mas, PhD^{3,16,17}, Gianfranco Spalletta, MD PhD^{13,18}, Guido A. van Wingen, PhD⁴, Je-Yeon Yun, MD PhD^{19,20}, Chris Vriend, PhD¹, H. Blair Simpson, MD PhD²¹, Daan van Rooij, PhD⁶, Marcelo Q. Hoexter, MD, PhD²², Martine Hoogman, PhD^{6,23}, Jan K. Buitelaar, MD PhD⁶, Paul Arnold, MD PhD²⁴, Jan C. Beucke, PhD^{25,26}, Francesco Benedetti, MD²⁷, Irene Bollettini, PhD²⁷, Anushree Bose, PhD²⁸, Brian P. Brennan, MD MMSc²⁹, Alessandro S. De Nadai, PhD³⁰, Kate Fitzgerald, MD³¹, Patricia Gruner, PhD³², Edna Grünblatt, PhD^{33,34,35}, Yoshiyuki Hirano, PhD³⁶, Chaim Huyser, MD PhD³⁷, Anthony James, MD³⁸, Kathrin Koch, PhD³⁹, Gerd Kvale, PhD², Luisa Lazaro, MD PhD⁴⁰, Christine Lochner, PhD⁴¹, Rachel Marsh, PhD²¹, David Mataix-Cols, PhD²⁷, Pedro Morgado, MD PhD^{42,43,44}, Takashi Nakamae, MD PhD⁴⁵, Tomohiro Nakao, MD PhD⁴⁶, Janardhanan C. Narayanaswamy, MD²⁸, Erika Nurmi, MD PhD⁴⁷, Christopher Pittenger, MD PhD⁴⁸, Y.C. Janardhan Reddy, MD²⁶, João R. Sato, PhD⁴⁹, Noam Soreni, MD⁵⁰, S. Evelyn Stewart, MD^{51,52,53}, Stephan F. Taylor, MD³¹, David Tolin⁵⁴, Sophia I. Thomopoulos, BA⁸, Dick J. Veltman¹, Ganesan Venkatasubramanian, MD PhD²⁸, Susanne Walitza, MD³¹, Zhen Wang, MD PhD^{55,56}, Paul M. Thompson, PhD⁸, Dan J. Stein, MD PhD⁵⁷, on behalf of the ENIGMA-OCD working group*.

corresponding author: Odile A. van den Heuvel, MD PhD

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Department of Anatomy, Amsterdam Neuroscience, Amsterdam, The Netherlands. oa.vandenheuvel@amsterdamumc.nl

*all additional names members ENIGMA-OCD working group (to be added under consortium name, so that paper is linked to these consortium members in PubMed, although not being full author):

Yoshinari Abe
Pino Alonso

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/hbm.24972](https://doi.org/10.1002/hbm.24972)

Francesca Assogna
Nerisa Banaj
Marcelo C. Batistuzzo
Silvia Brem
Valentina Ciullo
Jamie Feusner
Ignacio Martínez-Zalacaín
José M. Menchón
Euripedes C. Miguel
John Piacentini
Federica Piras
Yuki Sakai
Lidewij Wolters
Kei Yamada

Affiliations:

1. Amsterdam UMC, Vrije Universiteit Amsterdam, Dept Psychiatry, Dept Anatomy & Neurosciences, Amsterdam Neuroscience, Amsterdam, The Netherlands.
2. Bergen Center for Brain Plasticity, Haukeland University Hospital, Bergen, Norway.
3. Department of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain.
4. Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, The Netherlands.
5. Department of Language & Genetics, Max Planck Institute for Psycholinguistics, Nijmegen, the Netherlands.
6. Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands.
7. Icahn School of Medicine at Mount Sinai, New York, United States of America.
8. Imaging Genetics Center, Mark & Mary Stevens Institute for Neuroimaging & Informatics, Keck USC School of Medicine, Marina del Rey, CA, USA.
9. Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea.
10. Department of Brain & Cognitive Sciences, Seoul National University College of Natural Sciences Seoul, Korea.
11. Division of Child & Adolescent Psychiatry, UCLA Jane & Terry Semel Institute For Neuroscience, Los Angeles, CA, United States of America.
12. Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada.
13. Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
14. Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia.
15. Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia.
16. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
17. Department of Psychobiology and Methodology in Health Sciences, Universitat Autònoma de Barcelona, Spain.
18. Division of Neuropsychiatry, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, United States of America.
19. Seoul National University Hospital, Seoul, Republic of Korea.

20. Yeongeon Student Support Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
21. Center for OC and Related Disorders at the New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, United States of America.
22. Departamento e Instituto de Psiquiatria do Hospital das Clinicas, IPQ HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
23. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
24. Mathison Centre for Mental Health Research & Education and Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
25. Humboldt-Universität zu Berlin, Department of Psychology, Berlin, Germany.
26. Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden.
27. Department of Psychiatry and Clinical Psychobiology, Scientific Institute Ospedale, Milano, Italy.
28. Obsessive-Compulsive Disorder (OCD) Clinic Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
29. McLean Hospital, Harvard Medical School, Belmont, MA, United States of America
30. Department of Psychology, Texas State University, San Marcos, United States of America
31. Department of Psychiatry, University of Michigan Medical School, Michigan, United States of America.
32. Department of Psychiatry, Yale University, New Haven, CT, United States of America.
33. Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry, University of Zurich, Zurich, Switzerland.
34. Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland
35. Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
36. Research Center for Child Mental Development, Chiba University, Chiba, Japan.
37. De Bascule, academic center child and adolescent psychiatry, Amsterdam, The Netherlands.
38. Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
39. Department of Neuroradiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Germany.
40. Department of Child and Adolescent Psychiatry and Psychology, IDIBAPS, CIBERSAM, Department of Medicine, Faculty of Barcelona, Spain.
41. SAMRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry, Stellenbosch University, South Africa.
42. Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
43. ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
44. Clinical Academic Center-Braga, Braga, Portugal.
45. Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
46. Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan.
47. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles; Los Angeles, CA, United States of America.
48. OCD Research Clinic, Yale University, New Haven, CT, United States of America.
49. Center of Mathematics, Computing and Cognition. Universidade Federal do ABC, Santo André, Brazil.
50. Pediatric OCD Consultation Service, Anxiety Treatment and Research Center, McMaster University, Hamilton, Ontario, Canada.
51. Department of Psychiatry, University of British Columbia, Vancouver, Canada.
52. BC Mental Health and Addictions Research Institute, Vancouver, Canada.
53. BC Children's Hospital, Vancouver Canada
54. Anxiety Disorders Center, The Institute of Living, Hartford, CT, United States of America.

55. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
56. Institute of Psychological and Behavioral Science, Shanghai Jiao Tong University, Shanghai, P.R. China
57. SAMRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry & Neuroscience Institute, University of Cape Town.

Word count abstract: 248

Word count manuscript: 6,085

Number of tables: none

Number of figures: 3

Number of references: 74

Acknowledgements:

OAvdH is supported by Netherlands Organization for Scientific Research (NWO/ZonMW Vidi 91717306); CF is supported by funding from the Max Planck Society (Germany); NJ is supported by NIH R01MH117601 and R01AG059874; JO is supported by NIMH R01MH085900 and R01MH081864; LS is supported by the National Institute of Mental Health of the National Institutes of Health (R01MH117601) and a NHMRC Career Development Fellowship (1140764); CSM is supported by Carlos III Health Institute (PI16/00889; CPII16/00048); GAvW is supported by Netherlands Organization for Scientific Research (NWO/ZonMW Vidi 016.156.318); GS/FP is supported by the Italian Ministry of Health (RC13-14-15-16-17-18-19A); JYY is supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B03028464); HBS is supported by NIMH R01 MH104648 and R21 MH093889; MH is supported by a personal Veni grant of the Netherlands Organization for Scientific Research (NWO, grant number 91619115); JKB is supported by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number 278948 (TACTICS); PA is supported by Alberta Innovates Translational Health Chair in Child and Youth Mental Health and the Ontario Brain Institute; KF is supported by NIMH K23 MH082176 and Dana Foundation; PG is supported by NIH K23 MH115206; YH is supported by Brain/MINDS Beyond program from the Japan Agency for Medical Research and Development (AMED) (JP19dm0307002) and Japan Society for the Promotion of Science (JSPS) KAKENHI (16K04344 and 19K03309); KK is supported by a Deutsche Forschungsgemeinschaft (DFG) grant (KO 3744/7-1); LL is supported by the Marató TV3 Foundation grants (01/2010 and 091710); JYCR is supported by DST INSPIRE faculty grant (IFA12-LSBM-26) of the Department of Science and Technology and BT/06/IYBA/2012 of the Department of Biotechnology, Government of India; EN is supported by NIMH R01MH085900 and R01MH081864; JCN is supported by DST INSPIRE faculty grant (IFA12-LSBM-26) of the Department of Science and Technology and BT/06/IYBA/2012 of the Department of Biotechnology, Government of India; NS is supported by the Ontario Brain Institute; SES is supported by Canadian Institutes of Health Research, Michael Smith Foundation for Health Research, BC Children's Hospital Foundation; GV is supported by Wellcome-DBT India Alliance grant (500236/Z/11/Z); SW is supported by Swiss National Science Foundation Grant (No. 320030_130237); ZW is supported by National Natural Science Foundation of China (No. 81671340) and grants from Shanghai Municipal Health Commission (2019ZB0201); PMT is supported by NIH U54 EB020403; TN is supported by the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT KAKENHI No. 18K07608).

Disclosures:

OAvdH: Lecture honorarium Benecke. II: Data safety monitoring committee Lundbeck
HBS: Research Support from Biohaven Pharmaceuticals for mutisite industry-sponsored clinical trial, royalties from UpToDate Inc and Cambridge University Press, stipend from the American Medical Association for servicing as Associate Editor of JAMA Psychiatry. NJ: MPI of a research related grant from Biogen Inc, for work unrelated to the contents of this manuscript. JKB: has been in the past 3 years a consultant to / member of advisory board of / and/or speaker for Shire, Roche, Medice, and Servier - he is not an employee of any of these companies, and not a stock shareholder of any of these companies - he has no other financial or material support, including expert testimony, patents, royalties. BPB: Research support from Eli Lilly, Transcept Pharamaceuticals, and Biohaven Pharmaceuticals. Consulting fees from Rugen Therapeutics and Nobilis Therapeutics. DMC: royalties for contributing articles to UpToDate, Wolters Kluwer Health and for editorial work from Elsevier. PM: CME-related honoraria, or consulting fees from Angelini, AstraZeneca, Bial Foundation, Biogen, DGS-Portugal, Janssen-Cilag, Springer Healthcare and 2CA-Braga. EN: Medical/Scientific Advisory Boards: Teva Pharmaceuticals, Myriad Genetics. CP: Research support from Biohaven Pharmaceuticals for mutisite industry-sponsored clinical trial; royalties from Oxford University Press; consultant to Blackthorn Therapeutics, Teva Pharmaceuticals, Brainsway. NS: Research Support from Lundbeck LLC. SFT: Research support from Otsuka and Boehringer Ingelheim
PMT: PT received a grant from Biogen, Inc., for work unrelated to this study. DJS: research grants or consultancy honoraria from Lundbeck and Sun.

Data availability statement:

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Abstract

Neuroimaging has played an important part in advancing our understanding of the neurobiology of obsessive-compulsive disorder (OCD). At the same time, neuroimaging studies of OCD have had notable limitations, including reliance on relatively small samples. International collaborative efforts to increase statistical power by combining samples from across sites have been bolstered by the ENIGMA consortium; this provides specific technical expertise for conducting multi-site analyses, as well as access to a collaborative community of neuroimaging scientists. In this paper, we outline the background to, development of, and initial findings from ENIGMA's OCD working group, which currently consists of 47 samples from 34 institutes in 15 countries on 5 continents, with a total sample of 2,323 OCD patients and 2,325 healthy controls. Initial work has focused on studies of cortical thickness and subcortical volumes, structural connectivity, and brain lateralization in children, adolescents and adults with OCD, also including the study on the commonalities and distinctions across different neurodevelopment disorders. Additional work is ongoing, employing machine learning techniques. Findings to date have contributed to the development of neurobiological models of OCD, have provided an important model of global scientific collaboration, and have had a number of clinical implications. Importantly, our work has shed new light on questions about whether structural and functional alterations found in OCD reflect neurodevelopmental changes, effects of the disease process, or medication impacts. We conclude with a summary of ongoing work by ENIGMA-OCD, and a consideration of future directions for neuroimaging research on OCD within and beyond ENIGMA.

Key words:

ENIGMA, obsessive-compulsive disorder, MRI, volume, cortical thickness, surface area, meta-analysis, mega-analysis

Background

Since the 1980s, OCD researchers worldwide have made extensive use of neuroimaging (Behar et al., 1984; Luxenberg et al. 1988). OCD has a distinctive phenotype, with characteristic repetitive thoughts and intrusions (obsessions) and habitual behaviors (compulsions), and there was early evidence of the involvement of specific brain circuits and systems (Cummings, 1995). Early hypotheses regarding brain systems involved were based on clinical observations, including descriptions of OCD-like behaviors in patients with subcortical disorders, such as Huntington's disease (Cummings & Cummingham, 1992), Sydenham's chorea (Swedo et al., 1989), and pallidal (Laplane et al., 1989) and frontal lobe (Eslinger et al., 1985) lesions. Data obtained with human brain imaging in the late 1980s allowed detailed neurobiological models of OCD to be developed. These models initially focused on the striatum and orbitofrontal cortex, but were later refined to include more broadly interacting fronto-striatal, fronto-parietal, fronto-limbic, and cerebellar circuits (van den Heuvel et al., 2016; Stein et al., 2019).

The first brain imaging studies in OCD focused on brain morphometry and glucose metabolism, using computed tomography (CT) (e.g., Behar et al., 1984), single photon emission computed tomography (SPECT) and positron emission tomography (PET) (e.g., Rubin et al., 1995). In the 1990s, magnetic resonance imaging (MRI) began to dominate the field. High resolution structural MRI enabled morphometric analyses of subcortical volume and shape, cortical thickness and surface area, as well as cortical gyrification. Functional MRI (fMRI) began to be used to visualize brain activation patterns during specific states relevant to the disorder, using a range of emotional and cognitive paradigms that may be crucial in the disease, e.g. symptom provocation (Thorsen et al., 2018; Jaspers-Fayer et al., 2019), fear and extinction learning (Milad et al., 2013), response inhibition (Norman et al. 2019), planning (e.g., van den Heuvel et al., 2005), working memory (e.g., de Vries et al., 2014), and reversal learning (e.g., Remijnse et al., 2006).

In the past decade, imaging designs began to shift from analyzing specific regions of interest to studying whole-brain networks. Network approaches can be used to examine structural connectivity, using diffusion weighted imaging (DTI) (Radua et al., 2014; Piras et al. 2013) as well as structural covariance (Yun et al., 2019), and functional connectivity at rest (Gürsel et al., 2019) and during task performance (e.g., Douw et al., 2019). As with other neuroimaging studies, a key challenge has been the reproducibility of research findings, as most single center imaging studies have limited statistical power to detect effects of the disorder, while adequately controlling for multiple comparisons and heterogeneity in demographic and clinical characteristics. Although each individual

study differs in the choice of paradigms, a structural MRI scan is typically part of every study design, enabling meta-analyses of data across many samples, or mega-analyses of pooled raw MRI scans or MRI-extracted measures. Although technically more challenging, meta-analysis and mega-analysis of resting state fMRI (rsfMRI), and even task-based fMRI, are also possible (Adhikari et al., 2018; Adhikari et al. 2019; Yan et al., 2019).

The first worldwide data-sharing initiative: the OCD Brain Imaging Consortium

The first large single-center structural MRI study of OCD was published in 2004 by Pujol et al., based on MRI scans of 72 OCD patients and 72 controls, using voxel-based morphometry (VBM) (Pujol et al., 2004; Ashburner & Friston, 2000). Compared to healthy controls, OCD patients had, on average, smaller volumes for the medial frontal gyrus, medial orbitofrontal cortex and left insula-operculum, and greater volumes for the ventral part of the putamen and anterior cerebellum. The striatal finding was mainly driven by the older patients and those with longer disease duration. Pujol et al. (2004) also found that although these frontal-striatal abnormalities were present across the various subtypes of OCD, specific phenotypes showed additional neural alterations: aggressive obsessions and checking compulsions were associated with smaller right amygdala. Subsequently, these effects were largely replicated by the symptom dimension findings of van den Heuvel et al. (2009).

Multiple conventional meta-analyses of VBM studies were subsequently published in OCD (Radua et al., 2009; Radua et al., 2010; Rotge et al., 2010; Peng et al., 2012), using statistical methods to aggregate information on effect sizes, standard errors, and confidence intervals from primary published studies, in order to estimate overall effect size. To meta-analyze voxel-based data, an often-used approach is the signed differential mapping (SDM) method, developed by Radua (<https://www.sdmproject.com>). A meta-analysis using this method showed that compared to healthy controls, OCD patients have, on average, lower volumes of the dorsomedial prefrontal cortex (dmPFC) / dorsal anterior cingulate cortex (dACC) and greater volume of the bilateral striatum (mainly anterior putamen, extending into the caudate nucleus) (Radua & Mataix-Cols, 2009). In comparison to other anxiety disorders, smaller volume of the dmPFC/dACC was found across disorders, whereas OCD patients had greater pallidal volume than did patients with anxiety disorders (Radua et al., 2010). An even larger cross-disorder meta-analysis of brain volume across mental disorders, including 193 studies (15,892 subjects) in six diagnostic groups (schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, OCD, and anxiety disorders) showed that smaller volume of the dACC and bilateral insula/operculum was not specific to OCD, but was consistently present across all these psychiatric disorders (Goodkind et al., 2015).

These aggregate meta-analyses, based on published data, were highly informative, but still prone to publication bias, selective reporting in primary studies, large variations in data processing and analyses across studies influencing the results, and insufficient power to undertake detailed investigations of the associations between clinical characteristics and neuroimaging findings (Boedhoe et al., 2019). To address these limitations, the OCD Brain Imaging Consortium (OBIC) was initiated in 2010; this initiative aimed to increase statistical power by pooling raw MRI data from centers around the world. Harmonization of data quality control and data processing, all performed at a single center, would limit variation across data samples to just the variation in inclusion criteria and data acquisition. Six academic OCD centers (from Asia, Europe and South America) provided high-quality data from 412 adult OCD patients and 368 healthy controls. Using VBM, the OBIC consortium mega-analysis showed that compared to healthy controls, OCD patients had lower volume of the dmPFC, dACC and bilateral insula-operculum, largely replicating previous meta-analytic findings (Radua & Mataix-Cols, 2009; Radua et al., 2010; Goodkind et al., 2015), as well as greater volume of the cerebellum. Group-by-age interaction effects illustrated that some regions (e.g., putamen) show a relative preservation of volume in OCD with increasing age while other regions (e.g., temporal regions) show a relative loss of volume in OCD with increasing age. These findings are consistent with the initial study by Pujol et al. (2004), and suggest that increased volume of the striatum/pallidum is most prominent in older OCD patients, perhaps related to disease chronicity.

Using the same OBIC dataset, structural covariance analysis of four striatal regions and two amygdala regions was performed, showing increased covariance between the volume of the ventral-rostral putamen and the left inferior frontal gyrus/operculum. Consistent with the previous findings, this association was only significant in older OCD patients, suggesting that these alterations may develop over the course of the disease (Subira et al., 2016). In addition to this fronto-striatal finding, increased covariance was found between the right centromedial-superficial part of the amygdala and the ventromedial prefrontal cortex, consistent with the role of the limbic circuit in OCD, as evident in functional MRI studies on emotional processing in this disorder (Thorsen et al., 2018; Milad et al., 2013).

Whereas VBM measures volume or gray matter density in cortical regions at the voxel level (Ashburner & Friston, 2000), surface-based methods such as FreeSurfer calculate morphometric measures from geometric models of the cortical surface (Fischl & Dale, 2000). Abnormalities in regional volume as measured with VBM can be the result of altered cortical thickness (CTh), surface

area (SA), cortical folding or a combination of these. Where cortical thickness changes dynamically across the lifespan as a consequence of development, disease and environmental factors (Frye et al., 2010; Eyer et al., 2011), surface area and cortical folding are more indicative of early neurodevelopment (Mangin et al., 2010). Atlas-based approaches as used in FreeSurfer and voxel-based approaches as used in VBM also differ in their approach to and interpretation of subcortical regions: whereas VBM detects density differences at the voxel-level, global or regional differences in subcortical structures can be inferred from atlas-based FreeSurfer analyses. Using exactly the same OBIC sample as used in the VBM mega-analysis (de Wit et al., 2014), Fouche et al. (2017) used vertex-wise FreeSurfer to compare cortical thickness and subcortical volumes in patients versus controls, and showed that adult OCD patients have a thinner cortex in a number of frontal, temporal and parietal regions and smaller bilateral hippocampus. These findings partly overlap with the VBM-based results, but also show that results and their interpretation depend to some extent on the methods used.

Extension to children and better worldwide coverage: the ENIGMA-OCD consortium

In 2009, Paul Thompson initiated the ENIGMA (Enhancing Neuroimaging and Genetics through Meta-analysis) consortium. ENIGMA has now grown to a collaboration of more than 1,400 scientists from 43 countries studying the human brain, both in health and disease (Thompson et al., 2019). The initial aim was to perform large-scale neuroimaging genetics analyses, by pooling worldwide data, resources and expertise, to answer clinical and fundamental questions related to psychiatric and neurological disorders. The consortium currently has thirty working groups on specific psychiatric and neurological disorders, a few on trans-diagnostic constructs (e.g., irritability, suicidality, lifespan), and 12 that develop and disseminate analysis pipelines, to facilitate harmonization across working groups.

With the goals of obtaining larger sample sizes than represented in OBIC, increasing worldwide coverage, extending the samples to pediatric OCD, comparing OCD to other disorders, and eventually combining imaging data and genetics, van den Heuvel and Stein proposed adding an ENIGMA-OCD working group to the ENIGMA consortium in 2013. As of 2019, ENIGMA-OCD consists of 47 samples from 34 institutes in 15 countries on 5 continents, with a total sample of 4,648 with MRI data of 2,323 OCD patients (1,824 adults (>18 years), 359 adolescents (12-17 years), 140 children (<12 years)) and 2,325 controls (1,724 adults, 325 adolescents, 166 children).

>> insert figure 1 here: world map of the ENIGMA OCD consortium

The standard procedure in ENIGMA has been collation of individual-participant data (e.g., value of CTh, SA, subcortical volume, and intracranial volume) from multiple studies, without requiring the sharing or centralization of the raw MRI data, as was done in OBIC. The advantage of meta-analysis on individual-participant data (IPD) without the need to exchange raw data is of particular relevance in the context of the new European law, i.e., the General Data Protection Regulation 2016/679, regulating data protection and privacy for all individual citizens of the European Union (<https://gdpr-info.eu/>). Using standardized protocols for data processing and quality control (see also: <http://enigma.ini.usc.edu/protocols/>), all data are processed at each site locally.

Standardization of protocols, within working groups and across working groups, ensures low methodological heterogeneity across sites and working groups. IPD can subsequently be used in two different statistical approaches: a two-stage or a one-stage approach (Boedhoe et al., 2019). In the two-stage approach, IPD are first analyzed for each sample separately to obtain summary results (e.g. effect size estimates, confidence intervals, etc.), which are then used for standard meta-analysis. In contrast, the one-stage approach analyzes all IPD in one statistical model, while accounting for site effects, to estimate the overall effect. In the ENIGMA-OCD publications we call the two-stage approach *meta-analysis*, and the one-stage approach *mega-analysis*. Whereas in OBIC we conducted mega-analyses on the raw MRI data - all processed at a single site - in ENIGMA-OCD we conducted both the two-stage aggregated data meta-analyses and the one-stage IPD-based mega-analyses.

Within ENIGMA-OCD, the meta- and mega-analyses revealed comparable findings for the subcortical regions (Boedhoe et al., 2017), but the mega-analytic approach appeared more sensitive for detecting subtle cortical abnormalities (Boedhoe et al., 2018). We recently empirically evaluated whether a meta-analysis provides results comparable to a mega-analysis, and which of the two analytic frameworks (multiple linear regression mega-analysis model versus linear mixed-effects random-intercept mega-analysis model) performs better. Effect sizes and standard error estimates (and 95% confidence intervals), and (where possible) model fit, assessed using the Bayesian information criterion, were used to evaluate which of the methods performs best. Although effect sizes were similar for the meta-analysis and linear regression mega-analysis, we showed that in the case of cross-sectional structural MRI data a mega-analysis performs better than a meta-analysis (lower standard errors and narrower confidence intervals), and in a multi-center study with moderate variation between cohorts, a linear mixed-effects random-intercept mega-analytical framework seems to lead to the best model fit (Boedhoe et al., 2019).

First findings of ENIGMA-OCD: cortical thickness, surface area and subcortical volume

When comparing OCD patients to healthy controls, we analyzed data from adult subjects (18 years and older) and pediatric/adolescent subjects (below 18 years), separately. For the purpose of basic comparisons of subcortical volume and cortical thickness and surface area, we pooled data from children (<12 years) and adolescents (12-17 years) in a pediatric/adolescent analysis (Boedhoe et al., 2017; Boedhoe et al., 2018), but in the subsequent cross-disorder comparisons with other child-onset disorders (autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD)), we analyzed children and adolescents separately (Boedhoe et al., 2019).

In the subcortical analyses, we found clear differences between the pediatric OCD patients (compared with healthy controls, $n=335$ and 287 , respectively) and the adult OCD patients (compared with healthy controls, $n=1,495$ and $1,472$, respectively) (Boedhoe et al., 2017). Pediatric OCD was associated with greater volume of the thalamus (Cohen's $d=0.38$), but this effect was only detectable in the comparison of unmedicated OCD to versus healthy controls. We recently replicated this finding with data from the Generation R cohort (Jaddoe, et al., 2010), in which children with probable OCD (scoring above the cut-off on the short OCD screener) also had a larger thalamus, on average (unpublished data). This may suggest altered neurodevelopment in children prone to develop OCD. Nevertheless, the thalamus is not a uniform structure but rather consists of multiple subnuclei, each with its own cortical connectivity profile and functions (Behrens et al., 2003). OCD-related enlargement of the overall thalamus may therefore be driven by one or a few subnuclei. Which subnuclei drive this effect is currently unknown, although shape analysis has revealed increased surface area in anterior and pulvinar nuclei in adult OCD patients (Shaw et al., 2015). In future studies, we will employ the recently developed and validated algorithm from Iglesias et al. (2018) to segment the subnuclei of the thalamus and study which nuclei drive the effect.

Adult OCD patients showed smaller hippocampus (Cohen's $d=-0.13$), most pronounced in patients with an adult onset of OCD (Cohen's $d=-0.18$), patients with a comorbid lifetime diagnosis of depression (Cohen's $d=-0.27$), and patients using medication (Cohen's $d=-0.29$). Adult OCD patients also showed larger pallidum (Cohen's $d=0.16$), most pronounced in patients with a childhood onset of OCD (Cohen's $d=0.25$) and patients using medication (Cohen's $d=0.29$). The hippocampal findings do not seem to be specific to OCD, as similar results have been reported by the ENIGMA working groups for schizophrenia (van Erp et al., 2016), bipolar disorder (Hibar et al., 2016), major depressive disorder (Schmaal et al., 2016), and posttraumatic stress disorder (Logue et al., 2018),

and so may be related to trans-diagnostic aspects of chronic distress. The pallidum findings fit well with all prior meta- and mega-analyses (Radua & Mataix-Cols, 2009; Radua et al., 2010; Rotge et al., 2010; Peng et al., 2012; de Wit et al., 2014) and appear to be more specific to OCD. Larger pallidum could be due to chronic compulsivity (van den Heuvel et al., 2016). At the same time, since larger pallidum has also been reported in schizophrenia (van Erp et al., 2016), use of antipsychotic medication might partly explain the findings. Indeed, in our analysis by age-group and medication class (Ivanov et al. 2019), a larger pallidum was seen particularly in adolescent and adult patients taking antipsychotics.

Analyses of alterations in brain asymmetry, in partnership with ENIGMA's Laterality working group, showed that children/adolescents with OCD (n=501) versus healthy controls (n=439) have altered asymmetry of the thalamus (more leftward; Cohen's $d=0.19$) and pallidum (less leftward, Cohen's $d=-0.21$), which was not detectable in adult OCD, possibly reflecting altered neurodevelopmental processes (Kong et al., 2019).

>> insert figure 2 here: subcortical findings

The cortical analyses showed that pediatric/adolescent OCD patients (n=407) versus healthy control children/adolescents (n=324) have thinner left and right inferior parietal, left superior parietal and lateral occipital cortices (Cohen's d values between -0.24 and -0.31). Adult OCD patients (n=1,498) versus adult healthy controls (n=1,436) showed a lower surface area of the transverse temporal cortex (Cohen's $d=-0.16$) and a thinner bilateral inferior parietal cortex (Cohen's $d=-0.14$) (Boedhoe et al. 2018). The involvement of the parietal cortex is consistent with the vertex-wise FreeSurfer findings of the OBIC consortium (Fouche et al., 2017), and the effect was now further found to extend to children, suggesting altered maturation of the parietal cortex early in life that persists into adulthood. One obvious discrepancy with previous meta- and mega-analysis on structural MRI in OCD is the lack of involvement of the prefrontal regions; this may reflect differences in methods used: the atlas-based approach to cortical thickness and surface areas that has been used in ENIGMA (segmenting whole structures using coarse parcellation) can be less sensitive to subtle regional abnormalities than VBM's voxel-wise registration and vertex-based approach to cortical thickness that was used by OBIC. The use of higher-resolution parcellation methods (e.g., Glasser et al., 2016) might give results that are more consistent with the voxel-wise and vertex-wise approaches.

Medication status appeared to be a strong confounder (Boedhoe et al. 2018). Compared to healthy controls (n=324), pediatric/adolescent OCD patients on medication (n=183) had thinner inferior and

superior parietal and lateral occipital cortices (Cohen's $d=-0.31$) and widespread surface area differences, mainly in frontal regions (Cohen's d values between -0.27 and -0.33). Medicated adult OCD patients ($n=646$) versus controls ($n=1,436$) had widespread abnormalities in cortical thickness, mainly concerning the frontal, temporal, parietal and occipital regions (Cohen's d values between -0.10 and -0.26 , see Figure 3). Unmedicated pediatric/adolescent ($n=222$) and adult ($n=831$) OCD patients did not differ from healthy controls, on average, in cortical thickness and surface area. Medication effects were most pronounced in those patients using a combination of antidepressants and antipsychotics, and persisted after adjusting for disease severity and co-morbidity. Although these medication effects should be interpreted with caution due to the cross-sectional nature of the study design and lack of information on duration and dosage of medication use, they may suggest neuroplastic effects of medication on the brain, both in children and adults. Longitudinal studies of the long-term protective and potentially negative effects of antidepressants on the developing brain are non-existent. This knowledge gap is remarkable in the context of more than sixty years of antidepressant prescriptions. Solid conclusions on the impact of this medication on the brain await longitudinal studies, with detailed assessment of symptom profile, duration without treatment, medication dosage and duration of exposure, also taking into account the exposure to other interventions (e.g., CBT) and environmental factors (e.g., early life stress).

>> insert figure 3 here: medication effects on cortical morphometry

Using the available cross-sectional data of ENIGMA-OCD, we studied medication effects in two additional ways. First, we used machine learning analysis of the previously analyzed cortical and subcortical measures from 2,304 OCD patients and 2,068 controls to assess whether anatomical group differences might be used to create a neuroimaging biomarker for OCD (Bruin et al., 2019). Classification performance across ten different machine and deep learning approaches was limited, in this initial analysis that only used extracted measures derived from anatomical MRI. With site-stratified cross-validation, the receiver operating characteristic area under the curve (ROC-AUC) ranged between 0.57 and 0.62, and the performance dropped to chance level (classification performance between 0.51 and 0.54) when leave-one-site-out cross-validation was used, indicating that these anatomical brain features, on their own, are not suitable as a biomarker for OCD. However, when patients were stratified according to whether they currently use medication, classification performance improved remarkably: medicated OCD patients and healthy controls could then be distinguished with a 0.73 AUC (SD=0.03, $p_{\text{corr}}<0.001$) (in contrast to unmedicated OCD and healthy controls, with 0.61 AUC (SD=0.02, $p_{\text{corr}}=0.03$)), and medicated and unmedicated OCD patients with 0.86 AUC (SD=0.02, $p_{\text{corr}}<0.001$). These multivariate results therefore mirror the

univariate results, and highlight that medication use is associated with significant differences in brain anatomy.

In the second additional approach, we studied age-by-medication interactions in 2,176 OCD patients (1,040 medicated/1,136 unmedicated) and 2,003 healthy controls, using a general linear model (Ivanov et al. 2019). Medicated OCD patients, unmedicated OCD patients, and healthy controls all showed decreasing brain-wide cortical thickness, surface area, and subcortical volume with increasing age ($p < 0.0005$) in most regions. Effects of medication ($p < 0.001-0.0005$) and age-by-medication interactions ($p < 0.05-0.0005$) were detected in 46 cortical and 7 subcortical brain regions. Thereby, in certain regions (e.g., supramarginal gyrus, lateral occipital cortex), child and/or adolescent medicated OCD patients had thicker cortex than unmedicated patients. Adult medicated OCD patients, however, had thinner cortex than unmedicated OCD patients. Effects on cortical thickness were strongest for tricyclic antidepressants, but were also present for serotonin reuptake inhibitors (SRIs) and benzodiazepines. One (speculative) explanation of the differential effects of medication on cortical thickness in pediatric versus adult patients with OCD is the combination of treatment-associated slowing of the neuronal regressive changes (synapse loss and neurite pruning) and slowing (in children) and acceleration (in adults) of the progressive white-matter myelination of normal aging.

The first ENIGMA-OCD brain structural connectivity results

After conducting the initial meta- and mega-analyses of regional brain volumetric abnormalities, we initiated analyses of structural brain connectivity, using both structural covariance graph analyses (Yun et al., 2019) and diffusion tensor imaging (Piras et al., 2019). Brain structural covariance networks reflect covariation in morphology of different brain areas and are thought to reflect common trajectories in brain development and maturation, as well as common effects of a disorder (Hunt et al., 2016). Large-scale investigation of structural covariance networks are therefore of specific interest when studying neurodevelopmental disorders such as OCD that have chronic symptoms over the lifespan.

Using T1-weighted MRI derived measures of brain morphometry (bilaterally-averaged values of 33 cortical surface areas, 33 cortical thickness values, and six subcortical volumes) from OCD patients ($n=1,616$) and healthy controls ($n=1,463$), we calculated intra-individual brain structural covariance networks, in which edge weights were proportional to the similarity between two brain

morphological features in terms of deviation from controls (z-score transformed) (Yun et al., 2019). We focused on measures of network segregation (clustering and modularity), network integration (global efficiency), their balance (small-worldness), and community membership. We also studied hub profiling of regional brain areas using measures of betweenness, closeness, and eigenvector centrality. Individually calculated network measures were integrated across the 37 ENIGMA-OCD datasets using a meta-analytic approach. At the global level, compared to healthy controls, OCD patients showed lower clustering ($p < 0.0001$), modularity ($p < 0.0001$), small-worldness ($p = 0.017$), and community membership, suggesting lower network segregation. At the regional level, compared to healthy controls, OCD patients showed lower (rank-transformed) centrality values for caudate and thalamus volume, and surface area of paracentral cortex, suggesting an altered distribution of brain hubs. Centrality, mainly of the cingulate and orbitofrontal areas, was associated with OCD disease duration, indicative of greater involvement of these regions with chronicity.

Abnormalities in structural connectivity might be explained in part by microstructural alterations in white matter. A number of the ENIGMA-OCD sites ($n = 19$) also have diffusion tensor imaging (DTI) scans of the same participants used in the analyses of the T1-weighted MRI measures. We compared DTI-derived values for fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) in 25 brain regions of OCD patients ($n = 700$ adults and 174 children/adolescents) and healthy controls ($n = 645$ adults and 144 children/adolescents) (Piras et al., 2019). We meta-analyzed patient versus control differences across sites, adjusted for age and sex, and investigated potential associations with clinical characteristics, such as medication status, age of disease onset, duration of illness, and disease severity. Adult OCD patients showed significantly lower FA in the sagittal stratum (Cohen's $d = -0.21$) and posterior thalamic radiation (Cohen's $d = -0.26$). Lower FA in the sagittal stratum was associated with a younger age of onset ($z = 2.71$), longer duration of illness ($z = -2.09$) and a higher percentage of medicated patients in the cohorts studied ($z = -1.98$). No significant association with symptom severity was detected. Pediatric OCD patients did not show any detectable microstructural abnormalities compared to matched healthy controls. These results suggest that in adult OCD patients the reported microstructural alterations in projection and association fibers to posterior brain regions are partly related to disease course and medication status, and thus are likely more a consequence than a cause of disease.

Since brain morphometry is plastic and changes under the influence of daily behavior and network function, the next level of understanding is to link these morphometric features of disease to alterations in brain network function, using fMRI scans, both at rest and during specific cognitive or emotional states.

New perspectives with clinical relevance

The ENIGMA-OCD consortium has already demonstrated significant scientific relevance by increasing our understanding of the disorder. Large-scale worldwide collaboration has also been relevant to thinking through more effective and efficient ways of doing science by bringing together data, expertise, and a critical mass of investigators. Regarding clinical significance, the machine learning analyses of morphological measures of the brain are not yet valuable diagnostically (Bruin et al., 2019), and we certainly do not need an MRI scan to diagnose OCD. However, performance is likely to improve with the inclusion of multimodal features from diffusion-weighted and functional MRI. However, several important lessons with clinical relevance have emerged. One example is the unexpected, but robust finding that medication status and disease chronicity both have a marked impact on all brain measures analyzed to date. This has two direct implications: first, it emphasizes the importance of establishing longitudinal studies to examine the beneficial and potential harmful effects of medication on the developing brain and; second, the fact that disease chronicity is related to marked morphological alterations of the brain, might provide additional incentive to invest in the implementation of state-of-the-art interventions (e.g., exposure treatment requires significant scale up across the globe) and the development of innovative treatments for those who do not respond to the first line interventions.

Another example of clinical relevance of ENIGMA-OCD is the potential for discovering prognostic biomarkers, i.e. the prediction of treatment response based on morphometric and/or functional brain signatures. For instance, response to cognitive behavior therapy (CBT) has been linked to structural variability in the prefrontal cortex (Hoexter et al. 2013; Fullana et al., 2014) and activation and connectivity of the amygdala (Gottlich et al., 2015; Olatunji et al., 2014; Fullana et al., 2017). Prediction studies have been so far limited in sample size and therefore replicability of findings has been poor. We have now started using data from ENIGMA-OCD samples with longitudinal clinical data of 170 children with OCD (from 9 sites) and 315 adults with OCD (from 7 sites), to study how variation in morphological values (cortical thickness, surface area and subcortical volumetry) is related to variation in treatment response (Bertolin et al., 2019). Moreover, we expect that multimodal imaging approaches, combining data on morphological features with measurements of white matter integrity and information on network function using resting-state fMRI, will be more informative for predicting treatment response at the individual level using machine learning analyses.

Ongoing and future analyses within ENIGMA-OCD

As already shown in previous meta-analyses across related mental disorders, some neural correlates are common across mental disorders, whereas others are more disorder-specific (Radua et al., 2010; Goodkind et al., 2015). The ENIGMA consortium, with different working groups using the same pipelines for data processing and data analysis, is an ideal setting for studying common and distinct features of mental disorders. Our first attempt to do so focused on neurodevelopmental disorders in the impulsive-compulsive spectrum, comparing OCD with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Using structural T1-weighted MRI scans from 151 cohorts worldwide with data from patients with OCD (n=2,323), ASD (n=1,777), and ADHD (n=2,271), and matched healthy controls (n=5,827), we performed a mega-analysis of cortical thickness, surface area and subcortical volume across groups, with separate analyses for children (<12 years), adolescents (12-17 years) and adults (>18 years) (Boedhoe et al., 2019). We found no shared alterations among all three disorders (also not at uncorrected level), while shared alterations between any two disorders did not survive correction for multiple comparisons. Children with ADHD compared to those with OCD had smaller hippocampal volumes. Children and adolescents with ADHD also had smaller intracranial volume than control children and those with OCD or ASD. Adults with ASD showed thicker frontal cortices compared to adult controls and other clinical groups. OCD-specific alterations were not found across different age-groups and no surface area alterations were found across the disorders. Based on the literature, future cross-disorder comparisons between OCD and other anxiety disorders, as previously done by Radua et al. (2010), as well as comparison with schizophrenia, which is also characterized by a bigger pallidum (van Erp et al., 2016) may also be useful.

Another direction of research that is currently in preparation is the meta-analysis of resting-state functional MRI. Resting-state fMRI (rs-fMRI) can provide multiple measures of functional connectivity that are thought to index the communication between distinct brain regions. A recent meta-analysis based on reported findings in the literature found that multiple resting-state networks are affected in OCD (Gürsel et al., 2018). Moreover, a single-site study suggests that rs-fMRI can predict the outcome of CBT (Reggente et al., 2018). To obtain robust estimations of functional connectivity abnormalities in OCD, the consortium aims to perform functional connectivity analyses using the *fmriprep+* pipeline that has been developed by Veer and colleagues (Charité, Berlin). This pipeline uses the fMRI preprocessing stages from *fmriprep* (Esteban et al., 2018), and outputs various rs-fMRI measures such as resting-state networks based on independent components analysis and (partial) correlation matrices between distinct brain regions. Initially, the consortium will analyze average

group differences in these measures between OCD patients and controls, and subsequently use machine learning methods to determine whether rs-fMRI can provide a biomarker for OCD. Furthermore, the same methods will be used in order predict CBT outcome at the group and individual patient level. We hope that this endeavor will provide a biomarker for treatment outcome that generalizes to different sites, and thereby paves the way towards personalized treatment for OCD. In the future, we hope to extend rs-fMRI meta-analysis in ENIGMA-OCD to task-based fMRI, focusing on frequently used paradigms such as emotional processing, response inhibition (and other executive tasks), and decision making.

Advances in large-scale neuroimaging studies have allowed the characterization of distinct group differences in the macroscopic structure of the cerebral cortex, across several psychiatric disorders (Thompson et al., 2019). Using a new bioinformatics approach, named virtual histology, we can now link these macroscopic differences with microscopic histological features within the human cerebral cortex (Patel et al., 2018; Shin et al., 2018). In brief, virtual histology relates variation in cell-specific gene expression profiles across the 34 regions of the Desikan-Killiany atlas with profiles of group differences in cortical thickness across the same 34 regions (Desikan et al., 2006). This approach combines gene expression data from the Allen Human Brain Atlas (Hawrylycz et al., 2012), and cell-specific markers from single-cell RNA sequencing (Zeisel et al., 2015) with MRI derived measures. Profiles of group differences in cortical thickness are generated using a meta-analytic approach for each of the six major psychiatric disorders (ASD, ADHD, bipolar disorder, major depressive disorder, OCD, and schizophrenia). Currently, there are 12,006 cases and 14,842 controls contributing to these profiles. The goal of the project is to characterize cell types within the human cortex (neurons [pyramidal cells and interneurons] and glia [astrocytes, microglia, oligodendrocytes]) in which gene expression is correlated with differences in cortical thickness across disorders, in the hope of illustrating common and/or unique neurobiological correlates between these disorders.

Ultimately we would like to combine imaging data with genetic information. ENIGMA has developed pipelines for integrated analyses of both neuroimaging and genetic data. Some of this work has focused on common variants: Satizabal et al. (2019), for example, investigated nearly 40,000 individuals, and found that more than 45 genetic loci were significantly associated with subcortical volumes. Analyses indicated that associated genes are implicated in neurodevelopment, synaptic signaling, axonal transport, and other key processes. Other work has focused on CNVs: in the largest CNV neuroimaging study to date, for example, 15q11.2 BP1-BP2 structural variation was found associated with brain morphology and cognition, with deletion carriers being particularly affected

(van den Meer et al., 2019). There is a clear potential to extend such work to specific disorders such as OCD. In a proof of principle investigation, ENIGMA-OCD has explored the overlap in genetic contributions to subcortical volumes and OCD (Hibar et al., 2018); significant positive concordance was found between OCD risk variants and variants associated with greater nucleus accumbens and putamen volumes. Further work is needed to expand on these preliminary findings. While the combined imaging-genetics database is still small, a polygenic risk score approach may be a useful first step.

Limitations of the ENIGMA Approach

Three important methodological weaknesses of the ENIGMA-OCD concept should be mentioned. First, the data collection was done in the past, at a time when there was no plan to use the data in worldwide collaboration. Therefore, there has been no harmonization of data acquisition, either with respect to imaging data or with respect to inclusion criteria and clinical data. Various MRI machines (with different field strengths) and various scan sequences have been used with inevitable variations in data quality. In addition, the level of detail on the clinical phenotypes (disease severity, comorbidity, disease course, treatment history, etc.) is limited, so disallowing detailed analyses of symptom profiles or cross-disorder characteristics. Second, the data collection has been mostly cross-sectional, limiting our ability to answer questions related to disease course, effects of medication, and cause versus consequence of disease. Longitudinal data is highly warranted, and with the increase in pre-/post-treatment imaging studies, we expect that more longitudinal data will soon become available. Family and particularly twin studies could go a long way to disentangle vulnerability from disease chronicity and medication. Third, only some of the imaging samples also have genotyping data, presenting a challenge, since for imaging-genetic analyses large samples are needed.

Summary and future directions in global collaborations

ENIGMA-OCD has brought together OCD experts from all over the world to re-analyze historical MRI data using meta- and mega-analyses. This has not only resulted in important contributions to the literature on brain alterations in OCD, but has also stimulated international collaboration and sharing of OCD imaging data from sites across the globe. While as outlined earlier, there are many questions still to address in the growing ENIGMA-OCD dataset, the findings and the successful model of international collaboration has already spurred new studies. For example, to solve the lack of harmonization on data acquisition and the lack of detail on clinical profile and to address the

confound of medication in the ENIGMA-OCD dataset, five of the participating ENIGMA-OCD sites, representing five continents, are now funded by NIMH (PI: H. Blair Simpson) to conduct the largest neurocognitive and multimodal-imaging study in medication-free subjects with OCD to date. Specifically, we will recruit 250 medication-free adults with OCD, 100 unaffected adult siblings of individuals with OCD, and 250 healthy control subjects. All will receive clinical evaluation, neurocognitive assessment, and MRI, focusing on morphometry (T1-weighted MRI), structural connectivity (DTI), and functional connectivity (rs fMRI). To ensure harmonized data collection, we have developed detailed protocols to ensure cross-site reliability on clinical measures, standardized delivery of neurocognitive tasks, and optimal MRI data acquisition for data pooling (see Simpson et al., 2019 for details). Following best-practices used in large-scale imaging consortia, the MRI quality procedures include: harmonization of scan sequences to optimize scan quality across scanners; both human and physical phantom studies at study start, with repeat phantom studies and preprocessing of all scans in real-time to ensure maintenance of scan quality over the course of study recruitment. Other ENIGMA-OCD sites that start new data collection might consider using similar methods, to increase the number of samples with higher quality harmonized data.

To conclude, large scale data-sharing as facilitated by ENIGMA-OCD has accelerated discovery and generated novel hypotheses that are now being pursued. It has also created a model for large-scale global collaboration across OCD experts, and even more broadly, across working groups focused on a range of disorders and methodologies. By joining forces, we can help to shift the research model from local and mono-disciplinary to global and multidisciplinary, increase rigor and transparency, and accelerate discovery. In the end, we share a common goal: to develop a circuit-based approach to different cognitive and clinical dimensions of OCD that can help transform how OCD and related mental disorders are conceptualized, diagnosed, and ultimately treated around the world.

Figure legends:

Figure 1:

World map showing the 34 institutes participating in the ENIGMA-OCD consortium

Figure 2

Summary of the subcortical volume effects in ENIGMA-OCD (based on Boedhoe et al., 2017 Am J Psychiatry).

Figure 3

Summary of the cortical thickness effects in adult OCD patients compared to healthy controls in ENIGMA-OCD, in relation to medication status (based on: Boedhoe et al., 2018 Am J Psychiatry). Negative effect sizes d (ranging from light orange $d=-0.05$ to dark red $d=-0.15$) indicate thinner cortex in OCD compared to controls.

Note: We may need to get permission from the journal publisher to reproduce parts of the previously published figure

References

Adhikari, B.M., Jahanshad, N., Shukla, D., Glahn, D.C., Blangero, J., Fox, P.T., ..., Kochunov, P. (2018). Comparison of heritability estimates on resting state fMRI connectivity phenotypes using the ENIGMA analysis pipeline. *Human Brain Mapping*, 39, 4893-4902.

Adhikari, B.M., Jahanshad, N., Shukla, D., Turner, J., Grotegerd, D., Dannlowski, U., ..., Kochunov, P. (2019). A resting state fMRI analysis pipeline for pooling inference across diverse cohorts: an ENIGMA rs-fMRI protocol. *Brain Imaging and Behavior*, 13, 1453-1467.

Ashburner, J., Friston, K.J. (2000). Voxel-based morphometry, the methods. *Neuroimage*, 11, 805-21.

Behar, D., Rapoport, J., Berg, C.J., Denckla, M.B., Mann, L., Cox, C., ..., Wolfman, M.G. (1984). Computerized tomography and neuropsychological test measures in adolescents with obsessive-compulsive disorder. *The American Journal of Psychiatry*, 141, 363-369.

Behrens, T.E., Johansen-Berg, H., Woolrich, M.W., Smith, S.M., Wheeler-Kingshott, C.A., Boulby, P.A., ..., Matthews, P.M. (2003). Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. *Nature Neuroscience*, 7, 750-757.

Bertolin, S., Martinez-Zalacain, I., Boedhoe, P.S.W., Alonso, P., ENIGMA-OCD working group, Thompson, P.M., Menchon, J.M., Stein, D.J., van den Heuvel, O.A., Soriano-Mas, C. (2019). Prefrontal cortical thickness is associated with response to cognitive-behavioral therapy in children with OCD. Poster presented at the 32nd European College of Neuropsychopharmacology (ECNP) Congress.

Boedhoe, P.S.W., Schmaal, L., Abe, Y., Ameis, S.H., Arnold, P.D., Batistuzzo, M.C., ..., van den Heuvel, O.A. (2017). Distinct subcortical volume alterations in pediatric and adult OCD; a worldwide meta- and mega-analysis. *The American Journal of Psychiatry*, 174, 60-70.

Boedhoe, P.S.W., Schmaal, L., Abe, Y., Ameis, S.H., Antececic, A., Arnold, P.D., ..., van den Heuvel, O.A. (2018). Cortical abnormalities associated with pediatric and adult obsessive-compulsive disorder: findings from the ENIGMA Obsessive-Compulsive Disorder working group. *The American Journal of Psychiatry*, 175, 453-462.

Boedhoe, P.S.W., Heymans, M.W., Schmaal, L., Abe, Y., Alonso, P., Ameis, S.H., ..., van den Heuvel, O.A., Twisk, J.W.R. (2019). An empirical comparison of meta- and mega-analysis with data from the ENIGMA Obsessive-Compulsive Disorder working group. *Frontiers in Neuroinformatics*, 12, 102.

Boedhoe, P.S.W., van Rooij, D., Hoogman, M., ..., ENIGMA ADHD working group, ENIGMA ASD working group, ENIGMA OCD working group, Thompson, P.M., Stein, D.J., Buitelaar, J.K., Franke, B., van den Heuvel, O.A. (in press). Subcortical brain volume, regional cortical thickness and cortical surface areas across ADHD, ASD, and OCD: findings from the ENIGMA-ADHD, -ASD, and -OCD working groups. *The American Journal of Psychiatry* (revision) / or BioRxiv if not yet accepted

Bruin, W.B., Taylor, L., Thomas, R.M., Shock, J.P., Zhutovsky, P., ENIGMA-OCD consortium, ..., van Wingen, G.A. (2019). Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters. Preprint on MedRxiv doi: <https://doi.org/10.1101/19012567>

Cummings, J.L., Cunningham, K. (1992). Obsessive-compulsive disorder in Huntington's disease. *Biological Psychiatry*, 31, 263-270.

Cummings, J.L. (1995). Anatomic and behavioral aspects of frontal-subcortical circuits. *Annals of the New York Academy of Sciences*, 769, 1-13.

De Vries, F.E., de Wit, S.J., Cath, D.C., van der Werf, Y.D., van der Borden, V., van Rossum, T.B., ..., van den Heuvel, O.A. (2014). Compensatory fronto-parietal activity during working memory: an endophenotype of obsessive-compulsive disorder. *Biological Psychiatry*, 76, 878-87.

De Wit, S.J., Alonso, P., Schweren, L., Mataix-Col, D., Lochner, C., Menchon, J.M., ..., van den Heuvel, O.A. (2014). Multi-center voxel-based morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder. *The American Journal of Psychiatry*, 171, 340-349.

Desikan, R.S., Ségonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., ..., Hyman, B.T. (2006). An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*, 31, 968-980.

Douw, L., Quaak, M., Fitzsimmons, S.M.D.D., de Wit, S.J., van der Werf, Y.D., van den Heuvel, O.A., Vriend, C. (2019). Static and dynamic network properties of the repetitive transcranial magnetic stimulation target predict changes in emotion regulation in obsessive-compulsive disorder. *Brain Stimulation*, pii: S1935-861X(19)30426-7.

Eslinger, P.L., Damasio, A.R. (1985). Severe disturbance of higher cognition after bilateral frontal lobe ablation: patient EVR. *Neurology*, 35, 1731-41.

Esteban, O., Markiewicz, C.J., Blair, R.W., Moodie, C.A., Isik, A.I., Erramuzpe, A., ..., Gorgolewski, K.J. (2019). fMRIPrep: a robust preprocessing pipeline for functional MRI. *Nature Methods*, 16, 111-116.

Eyler, L.T., Prom-Wormley, E., Panizzon, M.S., Kaup, A.R., Fennema-Notestine, C., Neale, M.C., ..., Kremen, W.S. (2011). Genetic and environmental contributions to regional cortical surface area in humans: a magnetic resonance imaging twin study. *Cerebral Cortex*, 21, 2313-2321.

Fouche, J.P., du Plessis, S., Hattingh, C., Roos, A., Lochner, C., Soriano-Mas, C., ..., van den Heuvel, O.A. (2017). Cortical thickness in obsessive-compulsive disorder: multisite mega-analysis of 780 brain scans from six centers. *The British Journal of Psychiatry*, 210, 67-74.

Fischl, B., Dale, A.M. (2000). Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proceedings of the National Academy of Sciences of the United States of America*, 97, 11050-11055.

Frye, R.E., Liederman, J., Malmberg, B., McLean, J., Strickland, D., Beauchamp, M.S. (2010). Surface area accounts for the relation of gray matter volume to reading-related skills and history of dyslexia. *Cerebral Cortex*, 20, 2625-2635.

Fullana, M.A., Cardoner, N., Alonso, P., Subira, M., Lopez-Sola, C., Pujol, J., ..., Soriano-Mas, C. (2014). Brain regions related to fear extinction in obsessive-compulsive disorder and its relation to exposure therapy outcome: a morphometric study. *Psychological Medicine*, 44, 845-856.

Fullana, M.A., Zhu, X., Alonso, P., Cardoner, N., Real, E., Lopes-Sola, C., ..., Soriano-Mas, C. (2017). Basolateral amygdala-ventromedial prefrontal cortex connectivity predicts cognitive behavioural

therapy outcome in adults with obsessive-compulsive disorder. *Journal of Psychiatry and Neuroscience*, 42, 378-385

Glasser, M.F., Coalson, T.S., Robinson, E.C., Hacker, C.D., Harwell, J., Yacoub, E., ..., van Essen, D.C. (2016). A multi-modal parcellation of human cerebral cortex. *Nature*, 536, 171-178.

Goodkind, M., Eickhoff, S.B., Oathes, D.J., Jiang, Y., Chang, A., Jones-Hagata, L.B., ..., Etkin, A. (2015). Identification of a common neurobiological substrate for mental illness. *JAMA Psychiatry*, 72, 305-15.

Göttlich, M., Krämer, U.M., Kordon, A., Hohagen, F., Zurowski, B. (2015). Resting-state connectivity of the amygdala predicts response to cognitive behavioral therapy in obsessive-compulsive disorder. *Biological Psychology*, 111, 100-9.

Gursel, D.A., Avram, M., Sorg, C., Brandl, F., Koch, K. (2018). Frontoparietal areas link impairments of large-scale intrinsic brain networks with aberrant fronto-striatal interactions in OCD: a meta-analysis of resting-state functional connectivity. *Neuroscience and Biobehavioural Reviews*, 87, 151-160.

Hawrylycz, M.J., Levin, E.S., Guillozet-Bongaarts, A.L., Shen, E.H., Ng, L., Miller, J.A., ..., Riley, Z.L. (2012). An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature*, 489, 391.

Hibar, D.P., Westlye, L.T., van Erp, T.G., Rasmussen, J., Leonardo, C.D., Faskowitz, J., ..., Andreassen, O.A. (2016). Subcortical volumetric abnormalities in bipolar disorder. *Molecular Psychiatry*, 21, 1710-1716.

Hibar, D.P., Cheung, J.W., Medland, S.E., Mufford, M.S., Jahanshad, N., Dalvie, S., ..., Thompson, P.M. (2018). Significant concordance of genetic variation that increases both the risk for obsessive-compulsive disorder and the volumes of the nucleus accumbens and putamen. *British Journal of Psychiatry*, 213, 430-436.

Hoexter, M.Q., Dougherty, D.D., Shavitt, R.G., D'Alcante, C.C., Duran, F.L., Lopes, A.C., ..., Miguel, E.C. (2013). Differential prefrontal gray matter correlates of treatment response to fluoxetine or

cognitive-behavioral therapy in obsessive- compulsive disorder. *European Neuropsychopharmacology*, 23, 569-580.

Hunt, B.A., Tewarie, P.K., Mouglin, O.E., Geades, N., Jones, D.K., Singh, K.D., ..., Brooks, M.J. (2016). Relationships between cortical myeloarchitecture and electrophysiological networks. *Proceedings of the National Academy of Sciences of the United States of America*, 113, 13510-5.

Iglesias, J.E., Insausti, R., Lerma-Usabiaga, G., Bocchetta, M., van Leemput, K., Greve, D.N., ..., Paz-Alonso, P.M. (2018). A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology. *Neuroimage*, 183, 314-326.

Ivanov, I., Boedhoe, P.S.W., Stein, D.J., Thompson, P.M., van den Heuvel O.A., O'Neill, J., ENIGMA-OCD working group (2019). Psychopharmacological treatment for OCD on brain morphometry across the lifespan. Presentation at symposium 'The structure of the OCD brain: effects of medication, chronicity and disease-specificity' at the Society of Biological Psychiatry 74th annual meeting, Chicago.

Jaddoe, V.W., van Duijn, C.M., van der Heijden, A.J., Mackenbach, J.P., Moll, H.A., Steegers, E.A., ..., Hofman, A. (2010). The Generation R study: design and cohort update 2010. *European Journal of Epidemiology*, 25, 823-41

Jaspers-Fayer, F., Lin, S.Y., Chan, E., Ellwyn, R., Lim, R., Best, J., ..., Stewart, S.E. (2019). Neural correlates of symptom provocation in pediatric obsessive-compulsive disorder. *Neuroimage Clinical*, 24, 102034.

Kong, X.Z., Boedhoe, P.S.W., Abe, Y., Alonso, P., Ameis, S.H., Arnold, P.D., ..., Francks, C. (2019). Mapping cortical and subcortical asymmetry in obsessive-compulsive disorder: findings from the ENIGMA consortium. *Biological Psychiatry*, pii: S0006-3223(19)31292-2.

Laplane, D., Levasseur, M., Pillon, B., Baulac, M., Mazoyer, B., ..., Baron, J.C. (1989). Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions: a neuropsychological, magnetic resonance imaging and positron tomography study. *Brain*, 112, 699-725.

Logue, M.W., van Rooij, S.J.H., Dennis, E.L., Davis, S.L., Hayes, J.P., Stevens, J.S., ..., Marey, R.A. (2018). Smaller hippocampal volume in posttraumatic stress disorder: a multisite ENIGMA-PGC

study: subcortical volumetry results from posttraumatic stress disorder consortia. *Biological Psychiatry*, 83, 244-253.

Luxenberg, J.S., Swedo, S.E., Flamant, M.F., Friedland, R.P., Rapoport, J., Rapoport, S.I. (1988). Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. *American Journal of Psychiatry* 145, 1089-93.

Mangin, J.F., Jouvent, E., Cachia, A. (2010). In-vivo measurement of cortical morphology: means and meanings. *Current Opinion in Neurology* 23, 359-367.

Milad, M.R., Furtak, S.C., Greenberg, J.L., Keshaviah, A., Im, J.J., Falkenstein, M.J., ..., Wilhelm, S. (2013). Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit. *JAMA Psychiatry*, 70, 608-18.

Norman, L.J., Taylor, S.F., Liu, Y., Radua, J., Chye, Y. de Wit, S.J., ..., Fitzgerald, K. (2019). Error processing and inhibitory control in obsessive-compulsive disorder: a meta-analysis using statistical parametric maps. *Biological Psychiatry*, 85, 713-725.

Olatunji, B.O., Ferreira-Garcia, R., Caseras, X., Fullana, M.A., Wooderson, S., Speckens, A., ..., Mataix-Cols, D. (2014). Predicting response to cognitive behavioral therapy in contamination-based obsessive-compulsive disorder from functional magnetic resonance imaging. *Psychological Medicine*, 44, 2125-37.

Patel, Y., Shin, J., Gowland, P., Pausova, Z., Paus, T. (2018). Maturation of the Human Cerebral Cortex During Adolescence: Myelin or Dendritic Arbor? *Cerebral Cortex*, doi: 10.1093/cercor/bhy204.

Peng, Z., Lui, S.S., Cheung, E.F., Jin, Z., Miso, G., Jing, J., Chan, R.C. (2012). Brain structural abnormalities in obsessive-compulsive disorder: converging evidence from white matter and grey matter. *Asian Journal of Psychiatry*, 5, 290-6.

Piras, F., Piras, F., Caltagirone, C., Spalletta, G. (2013). Brain circuitries of obsessive-compulsive disorder: a systematic review and meta-analysis of diffusion tensor imaging studies. *Neuroscience and Biobehavioural Reviews*, 37, 2856-77.

Piras, F., Piras, F., Abe, Y., Agarwal, S.M., Anticevic, A., Ameis, S., ..., Spalletta G (2019). White matter microstructure and its relation to clinical features of obsessive-compulsive disorder: findings from the ENIGMA OCD Working Group. bioRxiv 855916. DOI: doi: <https://doi.org/10.1101/855916>

Pujol, J., Soriano-Mas, C., Alonso, P., Cardoner, N., Menchon, J.M., Deus, J., Vallejo, J. (2004). Mapping structural brain alterations in obsessive-compulsive disorder. *Archives of General Psychiatry*, 61, 720-30.

Radua, J., Mataix-Cols, D. (2009). Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. *British Journal of Psychiatry*, 195, 393-402.

Radua, J., van den Heuvel, O.A., Surguladze, S., Mataix-Cols, D. (2010). Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder versus other anxiety disorders. *Archives of General Psychiatry*, 67, 701-11.

Radua, J., Grau, M., van den Heuvel, O.A., Thiebaut de Schotten, M., Stein, D.J., Rodriguez, E.J., Catani, M., Mataix-Cols, D. (2014). Multimodal voxel-based meta-analysis of white matter abnormalities in obsessive-compulsive disorder. *Neuropsychopharmacology*, 39, 1547-57.

Reggente, N., Moody, T.D., Morfini, F., Sheen, C., Rissman, J., O'Neill, J., Feusner, J.D. (2018). Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive-compulsive disorder. *Proceedings of the National Academy of Sciences of the United States of America*, 115, 2222-2227.

Remijnse, P.L., Nielen, M.M., van Balkom, A.J., Cath, D.C., van Oppen, P., Uylings, H.B., Veltman, D.J. (2006). Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive-compulsive disorder. *Archives of General Psychiatry*, 63, 1225-36.

Rotge, J.Y., Langbour, N., Guehl, D., Bioulac, B., Jaafari, N., Allard, M., Aouizerate, B., Burbaud, P. (2010). Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation meta-analysis. *Neuropsychopharmacology*, 35, 686-91.

Rubin, R.T., Anath, J., Villanueva-Meyer, J., Trajmar, P.G., Mena, I. (1995). Regional ¹³³Xenon cerebral blood flow and cerebral ^{99m}Tc-HMPAO uptake in patients with obsessive-compulsive disorder before and during treatment. *Biological Psychiatry*, 38, 429-37.

Satizabal, C.L., Adams, H.H.H., Hibar, D.P., White, C.C., Knol, M.J., Stein, J.L., ..., Ikram, M.A. (2019). Genetic architecture of subcortical brain structures in 38.851 individuals. *Nature Genetics*, 51, 1624-1636.

Schmaal, L., Veltman, D.J., van Erp, T.G., Sämann, P.G., Frodl, T., Jahanshad, N., ..., Hibar, D.P. (2016). Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. *Molecular Psychiatry*, 21, 806-812.

Shaw, P., Sharp, W., Sudre, G., Wharton, A., Greenstein, D., Raznahan, A., ..., Rapoport, J. (2015). Subcortical and cortical morphological anomalies as an endophenotype in obsessive-compulsive disorder. *Molecular Psychiatry*, 20, 224-31.

Shin, J., French, L., Xu, T., Leonard, G., Perron, M., Pike, G.B., ..., Paus, T. (2018). Cell-Specific Gene-Expression Profiles and Cortical Thickness in the Human Brain. *Cerebral Cortex*, 28, 3267-3277.

Simpson, H.B., van den Heuvel, O.A., Miguel, E.C., Reddy, Y.C.J., Stein, D.J., Lewis-Fernández, R., ..., Wall, M. (2019). Toward Identifying Reproducible Brain Signatures of Obsessive-Compulsive Profiles: Rationale and Methods for a New Global Initiative. *BMC Psychiatry* (under review)

Stein, D.J., Costa, D.L.C., Lochner, C., Miguel, E.C., Reddy, Y.C.J., Shavitt, R.G., van den Heuvel, O.A., Simpson, H.B. (2019). Obsessive-compulsive disorder. *Nature Reviews Disease Primers*, 5, 52.

Subira, M., Cano, M., de Wit, S.J., Alonso, P., Cardoner, N., Hoexter, M.Q., ..., Soriano-Mas, C. (2016). Structural covariance of neostriatal and limbic regions in patients with obsessive-compulsive disorder. *Journal of Psychiatry and Neuroscience*, 41, 115-23.

Swedo, S.E., Rapoport, J.L., Cheslow, D.L., Leonard, H.L., Ayoub, E.M. (1989). High-prevalence of obsessive-compulsive symptoms in patients with Sydenham's Chorea. *The American Journal of Psychiatry*, 146, 246-249.

Thompson, P.M., Jahanshad, N., Ching, C.R.K., Salminen, L., Thomopoulos, S.I., Bright, J., ..., Zelman, V. (2019). ENIGMA and global neuroscience: a decade of large-scale studies of the brain in health and disease across more than 40 countries. Preprint on PsyArXiv, doi: 10.31234/osf.io/qnsh7, <https://psyarxiv.com/qnsh7>

Thorsen, A.L., Hagland, P., Radua, J., Mataix-Cols, D., Kvale, G., Hansen, B., van den Heuvel, O.A. (2018). Emotional processing in obsessive-compulsive disorder: a systematic review and meta-analysis of 25 functional neuroimaging studies. *Biological Psychiatry, Cognitive Neuroscience Neuroimaging*, 3, 563-571.

Van den Heuvel, O.A., Veltman, D.J., Groenewegen, H.J., Cath, D.C., van Balkom, A.J., van Hartkamp, J., Barkhof, F., van Dyck, R. (2005). Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. *Archives of General Psychiatry*, 62, 301-9.

Van den Heuvel, O.A., Remijnse, P.L., Mataix-Cols, D., Vrenken, H., Groenewegen, H.J., Uylings, H.B., van Balkom, A.J., Veltman, D.J. (2009). The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. *Brain*, 132, 853-68.

Van den Heuvel, O.A., van Wingen, G., Soriano-Mas, C., Alonso, P., Chamberlain, S.R., Nakamae, T., ..., Veltman, D.J. (2016). Brain circuitry of compulsivity. *European Neuropsychopharmacology*, 26, 810-27.

Van Erp, T.G., Hibar, D.P., Rasmussen, J.M., Glahn, D.C., Pearlson, G.D., Andreassen, O.A., ..., Turner, J.A. (2016). Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Molecular Psychiatry*, 21, 547-553.


Yan, C.G., Chen, X., Li, L., Castellanos, F.X., Bai, T.J., Bo, Q.J., ..., Zang, Y.F. (2019). Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. *Proceedings of the National Academy of Sciences of the United States of America*, 116, 9078-9083.

Yun, J.Y., Boedhoe, P.S.W., Vriend, C., Jahanshad, N., Yoshinari, A., Ameis, S.H., ..., Kwon, J.S. (2019). Brain structural covariance networks in obsessive-compulsive disorder: a graph analysis from the ENIGMA consortium. *Brain*, in press.

Zeisel, A., Muñoz-Manchado, A.B., Codeluppi, S., Lönnerberg, P., La Manno, G., Juréus, A., ..., Betsholtz, C. (2015). Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science*, 347, 1138-1142.




HBM_24972_Figure 1_ENIGMA OCD world map.png




HBM_24972_Figure 2_subcortical.tif


medicated OCD (n=646)
vs HC (n=1436)



unmedicated OCD (n=831)
vs HC (n=1436)



medicated OCD (n=646)
vs unmed. OCD (n=831)



HBM_24972_Figure 3_cortical.tif